More on REPL
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $10.00 |
|
|||
| Open | $9.98 | ||||
| 52 Wk High | $1.45 | ||||
| 52 Wk Low | $0.50 | ||||
| Day High | $10.44 | ||||
| Day Low | $9.91 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 2,571,740 | ||||
- Form 4 Replimune Group, Inc. For: Jun 01 Filed by: Sarchi Christopher
- Replimune (REPL) call put ratio 1 call to 1.2 put amid sharp rally
- Replimune presents final data for RP2 cancer treatment at oncology meeting
- JPMorgan Upgrades Replimune Group (REPL) to Neutral
- Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
- Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
- JPMorgan Upgrades Replimune Group (REPL) to Neutral
- Replimune (REPL) call put ratio 1.4 calls to 1 put as share price up 83%
- Form 8-K Replimune Group, Inc. For: May 29
- Replimune plans RP1 cancer drug resubmission after FDA talks
Entities mentioned with REPL
- FDA | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- 13G | View Related Stories »
- Earnings | View Related Stories »
- JPMorgan | View Related Stories »
- BMO Capital | View Related Stories »
- Show More...
